By Research and Markets (http://www.researchandmarkets.com/research/m23x4f/communityacquired) has announced the addition of the "Community-Acquired Infections - Pipeline Review, H2 2013" report to their offering.
'Community-Acquired Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Community-Acquired Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Community-Acquired Infections.
Scope
- A snapshot of the global therapeutic scenario for Community-Acquired Infections.
- A review of the Community-Acquired Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Community-Acquired Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Mentioned
Ranbaxy Laboratories Limited
Debiopharm International S.A.
Implicit Bioscience Limited
Tetraphase Pharmaceuticals Inc.
TechnoPhage SA
Melinta Therapeutics Inc.
For more information visit http://www.researchandmarkets.com/research/m23x4f/communityacquired
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious
Diseases
